Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited allotted 591,270 fully paid equity shares of Re. 1 each to eligible employees on November 4, 2026, when they exercised options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007.
Exercise prices applied to four groups: Re. 1 for 28,150 shares, Rs. 781.20 for 295,435 shares, Rs. 1,060.20 for 4,225 shares and Rs. 981.40 for 263,460 shares. The company’s table reports 835,272,555 total issued shares after allotment. A footnote separately reports total paid-up capital of Rs. 835,271,555, represented by 835,271,555 shares, and attributes the 1,000-share difference to shares forfeited in September 1988. The allotted shares rank pari passu with existing shares.
Dr Reddy's Laboratories Ltd (RDY) identifies CEO Erez Israeli in a notice proposing the sale of 460,726 sponsored ADRs, with an aggregate market value of $6,542,310. Merrill Lynch is named as broker, October 29, 2026 is the approximate sale date, and NYSE is listed as the exchange.
Dr. Reddy’s Laboratories Limited (RDY) made the transcript of its earnings call available for the quarter and half year ended September 30, 2026. The call was conducted on October 23, 2026, and the transcript was uploaded to the company’s website.
Dr. Reddy’s Laboratories Limited (RDY) reported that the USFDA classified the pre-approval and Good Manufacturing Practices inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, as Voluntary Action Indicated (VAI). The agency concluded that the inspection was officially closed under 21 CFR 20.64(d)(3).
Dr. Reddy’s Laboratories Limited made audio and video recordings available for its earnings call held on October 23, 2026, concerning unaudited financial results for the quarter and half year ended September 30, 2026.
Dr. Reddy’s Laboratories Limited enclosed Deloitte Haskins & Sells LLP’s limited review reports on its unaudited financial results for the quarter and half-year ended September 30, 2026. The reports address both consolidated and standalone results.
Dr. Reddy’s Laboratories Limited (RDY) reported consolidated revenue of ₹167.4 billion for the six months ended September 30, 2026, down 3.5% year over year, while profit attributable to equity holders fell 52% to ₹13.7 billion. EBITDA was ₹27.9 billion, down 40%, and profit before tax was ₹17.8 billion, down 52%. Net cash generated from operating activities was ₹4.4 billion, compared with ₹30.2 billion in the year-earlier half.
North American revenue fell 29% to ₹46.9 billion, which the company attributed largely to lower lenalidomide sales; India revenue rose 17% to ₹35.7 billion, and Q2 FY27 Emerging Markets revenue increased 24% to ₹20.6 billion. In August 2026, the company initiated a recall in Canada of Semaglutide batches due to elevated levels of an unspecified impurity above the approved specification limit and a packaging and labelling error; it recorded ₹710 million for expected product returns as a revenue reduction. Gross margin for the half was 49.4%, versus 55.8% a year earlier.
Dr. Reddy’s Laboratories (RDY) appointed Akhil Ravi as Head API and Services and Senior Management Personnel and inducted him into the Management Council, effective November 13, 2026. He will continue to be responsible for operations of Aurigene Pharmaceutical Services Ltd., a wholly owned subsidiary. Ravi is a related party as the son-in-law of G V Prasad, Co-Chairman and Managing Director. His profile describes nearly 19 years of experience and states that Aurigene.ai, an AI-enabled integrated drug discovery workflow whose implementation he led, supports approximately 30% of the drug discovery services business.
Dr. Reddy’s Laboratories Limited (RDY) reported unaudited results for the three and six months ended September 30, 2026. Quarterly revenue was Rs. 86,708 million, compared with Rs. 88,051 million a year earlier, while profit for the period was Rs. 9,134 million versus Rs. 14,268 million.
For the six months, revenue was Rs. 167,413 million versus Rs. 173,503 million, and profit for the period was Rs. 13,482 million versus Rs. 28,364 million. Net cash from operating activities was Rs. 4,357 million, compared with Rs. 30,202 million for the same 2025 period.
The company recorded inventory write-downs of Rs. 5,622 million for the six months, versus Rs. 3,450 million. This included a Rs. 2,230 million inventory provision and Rs. 167 million in associated costs for Semaglutide batches found out of specification due to an API issue during the three months ended June 30, 2026. Separately, an August 2026 Canadian Semaglutide recall, related to an unspecified impurity exceeding the approved specification limit and a packaging and labelling error, led to Rs. 710 million recorded for expected product returns; this recall issue was unrelated to the API issue.